New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
Evolus, Inc.
EOLS
Shape
US Flag

NASDAQ

Unprofitable

EPS improving

Unprofitable

EPS improving

1B

Drug Manufacturers - Specialty & Generic

Next Earning date - 06 Nov 2024

1B

Drug Manufacturers - Specialty & Generic

Next Earning date - 06 Nov 2024

16.27USD
Shape-0.19 ( -1.15%)
favorite-chart

Relative Strenght

61
favorite-chart

Volume Buzz

-43%
favorite-chart

Earning Acce

Yes
favorite-chart

Dist 52w H.

9%

Quote Panel

Shape
Updated October 29, 2024
1W 4.09 % 1M 0.43 % 3M 33.47 % 1Y 113.80 %

Key Metrics

Shape
  • Market Cap

    1.03B


  • Shares Outstanding

    63.09M


  • Share in Float

    54.46M


  • Dividende

    0


  • Earning Date

    06 Nov 2024


  • Price Target

    16.27


  • Average Volume

    595101


  • Beta

    1.314


  • Range

    7.44-17.82


  • Industry

    Drug Manufacturers - Specialty & Generic


  • Website

    https://www.evolus.com


  • Sector

    Healthcare


Fundamentals

Shape

N/A

P/E Ratio

4.34x

P/S Ratio

52.84x

P/B Ratio

6.3

Debt/Equity

-22.5%

Net Margin

$-0.9

EPS

How EOLS compares to sector?

P/E Ratio

Relative Strength

Shape

EOLS

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

$351M

Shape424%

2025-Revenue

$0.32

Shape-79%

2025-EPS

$224M

Shape-4701%

2025-EBITDA

Analyst rating

No Data Available

Last analyst upgrade/downgrade

Barclays

upgrade

Previous: Not converted

2024-01-29

Now: Overweight

Needham

initialise

Previous: Not converted

2022-06-24

Now: Buy

Earnings GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

N/A

-0.32
vs -0.26

Q4.22

arrow
arrow

N/A

-0.16
vs -0.29

Q1.23

arrow
arrow

N/A

-0.17
vs -0.27

Q2.23

arrow
arrow

N/A

-0.22
vs -0.38

Q3.23

arrow
arrow

N/A

-0.19
vs -0.32

Q4.23

arrow
arrow

N/A

-0.14
vs -0.16

Q1.24

arrow
arrow

N/A

-0.13
vs -0.17

Q2.24

arrow
arrow

N/A

-0.07
vs -0.22

Q3.24

arrow
arrow

N/A

-0.12
vs -0.19

Q4.24

arrow
arrow

N/A

-0.00
vs -0.14

Sales GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

+27%

33.9M  vs 26.7M

Q4.22

arrow
arrow

+26%

43.6M  vs 34.7M

Q1.23

arrow
arrow

+23%

41.7M  vs 33.9M

Q2.23

arrow
arrow

+33%

49.3M  vs 37.2M

Q3.23

arrow
arrow

+46%

49.3M  vs 33.9M

Q4.23

arrow
arrow

+40%

61M  vs 43.6M

Q1.24

arrow
arrow

+42%

59.3M  vs 41.7M

Q2.24

arrow
arrow

+36%

66.9M  vs 49.3M

Q3.24

arrow
arrow

+28%

63.2M  vs 49.3M

Q4.24

arrow
arrow

+27%

77.3M  vs 61M

Return on EquityShape

status-upQoQ

Q3.22

arrow
arrow

-69%

-0.69
vs -0.50

Q4.22

arrow
arrow

-71%

-0.71
vs -0.69

Q1.23

arrow
arrow

-213%

-2.13
vs -0.71

Q2.23

arrow
arrow

+261%

2.61
vs -2.13

Q3.23

arrow
arrow

+87%

0.87
vs 2.61

Q4.23

arrow
arrow

+57%

0.57
vs 0.87

Q1.24

arrow
arrow

-71%

-0.71
vs 0.57

Q2.24

arrow
arrow

-59%

-0.59
vs -0.71

Institutionnal OwnershipShape

status-upQoQ

Q3.22

arrow
arrow

129

129
vs 125

3%

Q4.22

arrow
arrow

121

121
vs 129

-6%

Q1.23

arrow
arrow

129

129
vs 121

7%

Q2.23

arrow
arrow

141

141
vs 129

9%

Q3.23

arrow
arrow

143

143
vs 141

1%

Q4.23

arrow
arrow

156

156
vs 143

9%

Q1.24

arrow
arrow

172

172
vs 156

10%

Q2.24

arrow
arrow

162

162
vs 172

-6%

Earnings Growth

Latest News